Esophageal cancer stem cells express PLGF to increase cancer invasion through MMP9 activation

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12749-12755

  Chen, Yue ^a   Jiang, Tinghui ^a   Mao, Aiwu ^a   Xu, Jianrong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer stem cells; Esophageal cancer; Matrix metalloproteinases 9; Metastasis; Placental growth factor

Indexed keywords

GELATINASE B; PLACENTAL GROWTH FACTOR; PLACENTA PROTEIN;

ADULT; AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CELL COUNT; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ESOPHAGEAL CANCER CELL LINE; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CLEAVAGE; TUMOR INVASION; ANIMAL; DISEASE MODEL; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR IMAGING; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MOLECULAR IMAGING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PREGNANCY PROTEINS; TRANSCRIPTIONAL ACTIVATION;

EID: 84925283311     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2601-x     Document Type: Article

References (24)

1. Umar SB, Fleischer DE. Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol. 2008;5:517–26. doi:10.1038/ncpgasthep1223.
2. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17:2–9.
3. Petersson M, Niemann C. Stem cell dynamics and heterogeneity: implications for epidermal regeneration and skin cancer. Curr Med Chem. 2012;19:5984–92.
4. Perez-Losada J, Balmain A. Stem-cell hierarchy in skin cancer. Nat Rev Cancer. 2003;3:434–43.
5. Dufour A, Overall CM. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci. 2013;34:233–42.
6. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789–91.
7. Xiao X, Prasadan K, Guo P, El-Gohary Y, Fischbach S, Wiersch J, et al. Pancreatic duct cells as a source of VEGF in mice. Diabetologia. 2014;57:991–1000.
8. Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, et al. Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem. 2013;288:8636–46.
9. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575–83.
10. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, Zhou D, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell. 2002;1:99–108.
11. Davidson B, Reich R, Risberg B, Nesland JM. The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh Patol. 2002;64:47–53.
12. Rhee JS, Coussens LM. RECKing MMP function: implications for cancer development. Trends Cell Biol. 2002;12:209–11.
13. Li B, Tsao SW, Li YY, Wang X, Ling MT, Wong YC, et al. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int J Cancer. 2009;125:2576–85.
14. Mroczko B, Kozlowski M, Groblewska M, Lukaszewicz M, Niklinski J, Laudanski J, et al. Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in the different histopathological types of esophageal cancer. Folia Histochem Cytobiol. 2008;46:471–8.
15. Kataoka M, Yamagata S, Takagi H, Thant A, Akiyama S, Iida K, et al. Matrix metalloproteinase 2 and 9 in esophageal cancer. Int J Oncol. 1996;8:773–9.
16. Shima I, Sasaguri Y, Arima N, Yamana H, Fujita H, Morimatsu M, et al. Expression of epidermal growth-factor (EGF), matrix metalloproteinase-9 (mmp-9) and proliferating cell nuclear antigen (pcna) in esophageal cancer. Int J Oncol. 1995;6:833–9.
17. Hori T, Yamashita Y, Ohira M, Matsumura Y, Muguruma K, Hirakawa K. A novel orthotopic implantation model of human esophageal carcinoma in nude rats: CD44H mediates cancer cell invasion in vitro and in vivo. Int J Cancer. 2001;92:489–96.
18. Zhou X, Qi Y. PlGF inhibition impairs metastasis of larynx carcinoma through MMP3 downregulation. Tumour Biol. 2014. doi:10.1007/s13277-014-2232-2.
19. Zins K, Thomas A, Lucas T, Sioud M, Aharinejad S, Abraham D. Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts. Int J Mol Sci. 2013;14:17958–71.
20. Li B, Wang C, Zhang Y, Zhao XY, Huang B, Wu PF, et al. Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene. 2013;32:2952–62.
21. Laurent J, Hull EF, Touvrey C, Kuonen F, Lan Q, Lorusso G, et al. Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors. Cancer Res. 2011;71:3781–91.
22. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell. 2010;141:178–90.
23. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene. 1999;18:2883–91.
24. Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol. 2013;25:254–64.